MIM
CBMG

MetLife Investment Management’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

MetLife Investment Management’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-6,205
Closed -$114K – 2334
2020
Q3 		$114K Buy
+6,205
New +$104K ﹤0.01% 2158
2020
Q2 		– Sell
-6,199
Closed -$98.1K – 2388
2020
Q1 		$98.1K Buy
+6,199
New +$100K ﹤0.01% 2092
2019
Q1 		– Sell
-6,244
Closed -$110K – 2605
2018
Q4 		$110K Buy
+6,244
New +$106K ﹤0.01% 2250

Other funds holding CBMG

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MetLife Investment Management's CBMG Position: Q4 2020 in Review

MetLife Investment Management sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q4 2020, closing a stake of 6,205 shares — an estimated $114K sold.

MetLife Investment Management first reported a position in CBMG in Q4 2018 and held it in 3 quarters. The position peaked at $114K in Q3 2020. 67 funds tracked by Wall St. Rank hold CBMG as of Q4 2020.

  • MetLife Investment Management reported no remaining Cellular Biomedicine Group, Inc. position as of Q4 2020 after selling out during the quarter.
  • MetLife Investment Management sold 6,205 Cellular Biomedicine Group, Inc. shares in Q4 2020, an estimated $114K.
  • MetLife Investment Management first reported a position in Cellular Biomedicine Group, Inc. in Q4 2018 and held it in 3 quarters.
  • MetLife Investment Management's Cellular Biomedicine Group, Inc. position peaked at $114K in Q3 2020.
  • 67 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q4 2020.

Based on MetLife Investment Management's 13F filing for Q4 2020, filed 16 Feb 2021.